Status:
TERMINATED
Intensive Versus Regular Dosage For PD In AKI.
Lead Sponsor:
Peking University First Hospital
Conditions:
Peritoneal Dialysis
Acute Kidney Injury
Eligibility:
All Genders
14+ years
Phase:
NA
Brief Summary
This is a multicenter, pilot RCT study, aiming to compare intensive dosage and regular dosage of PD for AKI patients with indications for dialysis. Aims of the study are to: Examine the feasibility ...
Detailed Description
The incidence of acute kidney injury (AKI) is rapidly increasing worldwide, which partly due to greater recognition of AKI, more exposure to various nephrotoxins and an ageing population with increase...
Eligibility Criteria
Inclusion
- Age older than 14 years;
- Be diagnosed as AKI according to KDIGO recommendation;
- Having indications for renal replacement therapy.
Exclusion
- Having contraindications to peritoneal dialysis;
- Functional azotemia;
- Hypercatabolic status;
- Previous CKD history (baseline eGFR\<60ml/min/1.73m2 or proteinuria);
- Psychological disorder or communication barrier;
- Pregnancy;
- Refusing to receive dialysis therapy.
- receiving mechanical ventilation.
Key Trial Info
Start Date :
September 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 26 2019
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03438877
Start Date
September 29 2018
End Date
December 26 2019
Last Update
December 8 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Renal Division and Institute of Nephrology, Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
2
Cangzhou central hospital
Cangzhou, Hebei, China
3
Nanyang City Center Hospital
Nanyang, Henan, China
4
Pingdingshan People's Hospital No.1
Pingdingshan, Henan, China